AAL

Epilepsy Drug Data Sends CBD Specialist to Record Highs

Plus, GW Pharmaceuticals reported a slimmer-than-expected loss

Managing Editor
May 7, 2019 at 9:56 AM
facebook X logo linkedin


The shares of GW Pharmaceuticals PLC (NASDAQ:GWPH) are in focus today, after a double-dose of good news last night. First, the drugmaker's first-quarter loss was slimmer than expected. But more importantly, its epilepsy drug Epidiolex met the main goals in a late-stage study, while first-quarter sales for the drug were higher than expected. 

In response, GWPH is up 8.1% to trade at $194.75, and earlier nabbed a fresh record high of $196. Since a late-February earnings-induced bull gap, the shares had consolidated below the $180 level. Not only is this former resistance toppled today, but the security is on track for its fourth straight win, and has extended its year-to-date lead to 92%. 

The news has been met with no fewer than six price-target hikes too, the highest being to $234 from $227 at Morgan Stanley. The stock is no stranger to bull notes though, with 10 of 11 brokerages in coverage rating it a "buy" or better, and the average 12-month price target sits all the way up at $218.42. 

Short sellers may be ready to hit the exits. Short interest increased by 7.5% in the most recent reporting period to 3.10 million shares. This represents 12.2% of the stock's total available float, and 8.2 days' worth of pent-up buying power, at its average pace of trading.

 

Two High-Octane Trade Ideas. One Simple Goal: Intraday Profits.

Dynamite Day Trading Signals delivers two same-day options trades every week — powered by proprietary intraday analysis and 43+ years of trading expertise.

But this isn’t just another stream of alerts.

It’s a structured plan with clear entry and exit points – designed for traders who want to act fast, trade smart, and wrap up gains before the closing bell.

No guesswork. No overnight exposure – Just two well-researched setups per week — whether you prefer buying premium or selling it.

And the results speak for themselves: subscribers have locked in +245.8% total profit over the last six months (since inception!).

👉 Start your one-month trial now for just $10, and be ready for the next trade alert.